Appendix 4D and FY26 Half Year Report

• FDA clearance and CMS reimbursement of CT:VQ™, the world's first non-contrast, CT-based ventilation-perfusion imaging technology
• Rapid adoption of CT:VQ™ by leading U.S. Academic Medical Centers
• Philips' North American CT:VQ™ commercial contract unlocks mass distribution

4DMEDICAL Ltd (ASX:4DX) reported a transformational first half of FY26, highlighted by the FDA clearance and CMS reimbursement of its CT:VQ™ technology, the world's first non-contrast, CT-based ventilation-perfusion imaging solution. Within four months of FDA clearance, CT:VQ™ was adopted by five leading U.S. Academic Medical Centers, including Stanford University, Cleveland Clinic, and UC San Diego Health. 4DMEDICAL also announced a significant expansion of its distribution agreement with Philips, enabling the global healthcare company to distribute CT:VQ™ across the U.S. and Canada, with a minimum revenue commitment of approximately A$15 million over two years. The company continued to make strong progress in Australia, supporting the National Lung Cancer Screening Program and signing a pilot agreement with Royal Melbourne Hospital. In Brazil, 4DMEDICAL partnered with AstraZeneca to expand a lung health screening program across multiple hospitals. The company also raised A$150 million through an institutional placement to accelerate the commercialization of CT:VQ™ and invest in its product portfolio and growth initiatives.

4DMEDICAL is well-positioned to drive the global adoption of its advanced imaging and AI solutions, particularly the newly FDA-cleared and CMS-reimbursed CT:VQ™ technology. The company's strong commercial momentum, strategic partnerships, and robust balance sheet provide a solid foundation for accelerated growth and expansion into new markets.